Actuate Therapeutics (NASDAQ:ACTU) Shares Down 2.1% – Time to Sell?

Actuate Therapeutics (NASDAQ:ACTU) shares traded down 2.1% during mid-day trading on Tuesday . The stock traded as low as $7.85 and last traded at $8.11. 42,680 shares were traded during trading, an increase of 5% from the average session volume of 40,795 shares. The stock had previously closed at $8.28.

Actuate Therapeutics Trading Down 2.1 %

The firm has a 50-day moving average price of $8.37.

Institutional Investors Weigh In On Actuate Therapeutics

An institutional investor recently bought a new position in Actuate Therapeutics stock. Northwestern University bought a new stake in Actuate Therapeutics (NASDAQ:ACTU) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 27,778 shares of the company’s stock, valued at approximately $207,000. Actuate Therapeutics accounts for about 0.2% of Northwestern University’s portfolio, making the stock its 5th biggest holding. Northwestern University owned 0.14% of Actuate Therapeutics at the end of the most recent quarter.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.